{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T04:19:18Z","timestamp":1760242758111},"reference-count":92,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","geriatric.theclinics.com","theclinics.com","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Geriatric Medicine"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1016\/j.cger.2015.08.006","type":"journal-article","created":{"date-parts":[[2015,11,26]],"date-time":"2015-11-26T03:00:18Z","timestamp":1448506818000},"page":"175-189","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders"],"prefix":"10.1016","volume":"32","author":[{"given":"Sarah","family":"Wall","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A.","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cger.2015.08.006_bib1","unstructured":"Chronic lymphocytic leukemia - SEER stat fact sheets. 2015. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/clyl.html. Accessed May 20, 2015."},{"key":"10.1016\/j.cger.2015.08.006_bib2","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/10428190701724785","article-title":"Comorbid conditions and survival in unselected, newly diagnosed patients with chronic lymphocytic leukemia","volume":"49","author":"Thurmes","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cger.2015.08.006_bib3","unstructured":"Non-Hodgkin's lymphomas [Version 2.2015]. 2015. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nhl.pdf. Accessed May 20, 2015."},{"key":"10.1016\/j.cger.2015.08.006_bib4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/leu.2009.287","article-title":"Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical management","volume":"24","author":"Shanafelt","year":"2010","journal-title":"Leukemia"},{"key":"10.1016\/j.cger.2015.08.006_bib5","doi-asserted-by":"crossref","first-page":"258917","DOI":"10.1155\/2014\/258917","article-title":"New insights into monoclonal B-cell lymphocytosis","volume":"2014","author":"Kalpadakis","year":"2014","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.cger.2015.08.006_bib6","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2012.187","article-title":"Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls","volume":"27","author":"Moreira","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.cger.2015.08.006_bib7","unstructured":"Solomon BM, Rabe KG, Moreira J, et\u00a0al. Risk of cancer in patients with clinical monoclonal B-cell lymphocytosis (MBL): A cohort study of newly diagnosed patients compared to controls. Poster presented at the 54th Annual Meeting of the American Society of Hematology. Atlanta, GA, December 8-11, 2012."},{"key":"10.1016\/j.cger.2015.08.006_bib8","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A\u00a0new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.cger.2015.08.006_bib9","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocytic leukemia","volume":"46","author":"Rai","year":"1975","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib10","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJM199009133231105","article-title":"Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities","volume":"323","author":"Juliusson","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib11","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1182\/blood-2005-05-2093","article-title":"Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia","volume":"107","author":"Mayr","year":"2005","journal-title":"Blood"},{"issue":"Suppl 2","key":"10.1016\/j.cger.2015.08.006_bib12","first-page":"S19","article-title":"Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: specific chromosome aberrations identify prognostic subgroups of patients and point to loci of candidate genes","volume":"11","author":"Dohner","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.cger.2015.08.006_bib13","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib14","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib15","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib16","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1182\/blood-2009-08-207126","article-title":"How I treat CLL up front","volume":"115","author":"Gribben","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib17","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3109\/10428199409056283","article-title":"Infections in chronic lymphocytic leukemia: risk factors, and impact on survival, and treatment","volume":"13","author":"Molica","year":"1994","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cger.2015.08.006_bib18","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.1975.03250030023012","article-title":"Subsequent neoplasia in chronic lymphocytic leukemia","volume":"232","author":"Manusow","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.cger.2015.08.006_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/j.1365-2141.2011.08707.x","article-title":"Autoimmune cytopenia in chronic lymphocytic leukaemia: diagnosis and treatment","volume":"154","author":"Hodgson","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cger.2015.08.006_bib20","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/1097-0142(19811201)48:11<2447::AID-CNCR2820481118>3.0.CO;2-B","article-title":"Prolymphocytic transformation of chronic lymphocytic leukemia","volume":"48","author":"Kjeldsberg","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.cger.2015.08.006_bib21","unstructured":"Schweighofer CD, Cymbalista F, Muller C, et\u00a0al. Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia \u2013 first results of a randomized German-French cooperative phase III trial. Paper presented at the 55th Annual Meeting of the American Society of Hematology. New Orleans, LA, December 7-10, 2013."},{"key":"10.1016\/j.cger.2015.08.006_bib22","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib23","series-title":"Evaluation of chemotherapeutic agents","first-page":"191","article-title":"The clinical evaluation of chemotherapeutic agents in\u00a0cancer","author":"Karnofsky","year":"1949"},{"key":"10.1016\/j.cger.2015.08.006_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib25","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1532-5415.1968.tb02103.x","article-title":"Cumulative illness rating scale","volume":"16","author":"Linn","year":"1968","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.cger.2015.08.006_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.6004\/jnccn.2014.0009","article-title":"Senior adult oncology, version 2.2014: clinical practice guidelines in oncology","volume":"12","author":"Hurria","year":"2014","journal-title":"J\u00a0Natl Compr Canc Net"},{"key":"10.1016\/j.cger.2015.08.006_bib27","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1200\/JCO.2007.10.6559","article-title":"Comprehensive geriatric assessment for older patients with cancer","volume":"25","author":"Extermann","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib28","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428190802688517","article-title":"Treatment of elderly patients with chronic lymphocytic leukemia","volume":"50","author":"Eichhorst","year":"2009","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cger.2015.08.006_bib29","doi-asserted-by":"crossref","unstructured":"Eichhorst B, Fink A-M, Busch R, et\u00a0al. Frontline chemoimmunotherapy with fludarabine (F), cyclophosphamide (C), and rituximab (R) (FCR) shows superior efficacy in comparison to bendamustine (B) and Rituximab (BR) in previously untreated and physically fit patients (pts) with advanced chronic lymphocytic leukemia (CLL): final analysis of an international, randomized study of the German CLL Study Group (GCLLSG) (CLL10 study). Paper presented at the 56th Annual Meeting of the American Society of Hematology. San Francisco, CA, December 6-9, 2014.","DOI":"10.1182\/blood.V124.21.19.19"},{"key":"10.1016\/j.cger.2015.08.006_bib30","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2015.08.006_bib31","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1182\/blood-2009-02-206185","article-title":"First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia","volume":"114","author":"Eichhorst","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib32","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2011.41.5646","article-title":"Impact of age on outcomes after initial therapy with chemotherapy and different chemoimmunotherapy regimens in patients with chronic lymphocytic leukemia: results of sequential cancer and leukemia group B studies","volume":"31","author":"Woyach","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib33","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","article-title":"Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions","volume":"370","author":"Goede","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib34","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as frontline treatment of chronic lymphocytic leukemia: updated results of the CLL11 study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"10.1016\/j.cger.2015.08.006_bib35","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1016\/S0140-6736(15)60027-7","article-title":"Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial","volume":"385","author":"Hillmen","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2015.08.006_bib36","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib37","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1182\/blood-2014-10-606038","article-title":"Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib","volume":"125","author":"Byrd","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib38","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib39","unstructured":"Non-Hodgkin lymphoma - SEER stat fact sheets. 2015. Available at: http:\/\/seer.cancer.gov\/statfacts\/html\/nhl.html. Accessed May 20, 2015."},{"key":"10.1016\/j.cger.2015.08.006_bib40","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1002\/cncr.29290","article-title":"Disease characteristics, patterns of care, and survival in very elderly patients with diffuse large B-cell lymphoma","volume":"121","author":"Williams","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.cger.2015.08.006_bib41","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1002\/ijc.27889","article-title":"Unbiased estimates of long-term net survival of hematological malignancy patients detailed by major subtypes in France","volume":"132","author":"Monnereau","year":"2012","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cger.2015.08.006_bib42","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jgo.2014.11.004","article-title":"Diffuse large B-cell lymphoma in the elderly: impact of prognosis, comorbidities, geriatric assessment, and supportive care on clinical practice. An International Society of Geriatric Oncology (SIOG) expert position paper","volume":"6","author":"Morrison","year":"2014","journal-title":"J\u00a0Geriatr Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib43","doi-asserted-by":"crossref","first-page":"5103","DOI":"10.1182\/blood-2010-07-259333","article-title":"How I treat elderly patients with diffuse large B-cell lymphoma","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib44","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/cncr.23608","article-title":"Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004","volume":"113","author":"Zhou","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.cger.2015.08.006_bib45","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.3109\/10428194.2012.760041","article-title":"An upward trend in the age-specific incidence patterns for mantle cell lymphoma in the USA","volume":"54","author":"Aschebrook-Kilfoy","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cger.2015.08.006_bib46","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ajh.23708","article-title":"The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras","volume":"89","author":"Nabhan","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cger.2015.08.006_bib47","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib48","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1200\/JCO.2013.53.5229","article-title":"Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group","volume":"32","author":"Barrington","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib49","doi-asserted-by":"crossref","first-page":"3507","DOI":"10.1182\/blood-2007-06-097238","article-title":"The role of FDG-PET scans in patients with lymphoma","volume":"110","author":"Seam","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib50","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib51","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mds429","article-title":"Examination of the Follicular Lymphoma International Prognostic Index (FLIPI) in the National LymphoCare study (NLCS): a prospective US patient cohort treated predominantly in community practices","volume":"24","author":"Nooka","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib52","first-page":"635","article-title":"Assessment of the prognostic indices IPI and FLIPI in patients with mucosa-associated lymphoid tissue lymphoma","volume":"30","author":"Troch","year":"2010","journal-title":"Anticancer Res"},{"key":"10.1016\/j.cger.2015.08.006_bib53","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/cncr.27704","article-title":"Prognostic value of the Follicular Lymphoma International Prognostic Index score in marginal zone lymphoma: an analysis of clinical presentation and outcome in 144 patients","volume":"119","author":"Heilgeist","year":"2012","journal-title":"Cancer"},{"key":"10.1016\/j.cger.2015.08.006_bib54","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/bjh.13399","article-title":"Disease characteristics, treatment patterns, prognosis, outcomes and lymphoma-related mortality in elderly follicular lymphoma in the United States","volume":"170","author":"Nabhan","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cger.2015.08.006_bib55","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.cger.2015.08.006_bib56","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A\u00a0new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Choi","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.cger.2015.08.006_bib57","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib58","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1016\/j.biocel.2007.04.026","article-title":"The cellular origin of mantle cell lymphoma","volume":"39","author":"Bertoni","year":"2007","journal-title":"Int J Biochem Cell Biol"},{"key":"10.1016\/j.cger.2015.08.006_bib59","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.clml.2014.12.012","article-title":"Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma","volume":"15","author":"Cohen","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.cger.2015.08.006_bib60","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1053\/S0046-8177(03)00410-6","article-title":"Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes","volume":"34","author":"Nodit","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.cger.2015.08.006_bib61","doi-asserted-by":"crossref","first-page":"5307","DOI":"10.1158\/0008-5472.CAN-12-1615","article-title":"Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features","volume":"72","author":"Navarro","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.cger.2015.08.006_bib62","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1200\/JCO.2007.13.6929","article-title":"Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014","volume":"26","author":"Persky","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib63","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib64","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S1470-2045(13)70122-0","article-title":"Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial","volume":"14","author":"Delarue","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib65","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.3324\/haematol.13273","article-title":"Autologous stem cell transplantation in elderly patients (> or\u00a0=60 years) with diffuse large B-cell lymphoma: an analysis based on data in the European Blood and Marrow Transplantation registry","volume":"93","author":"Jantunen","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.cger.2015.08.006_bib66","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/j.bbmt.2008.09.008","article-title":"Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center for International Blood & Marrow Transplant Research (CIBMTR)","volume":"14","author":"Lazarus","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.cger.2015.08.006_bib67","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00000421-199706000-00022","article-title":"Evaluation of long-term daily administration of oral low-dose etoposide in elderly patients with relapsing or refractory non-Hodgkin's lymphoma","volume":"20","author":"Niitsu","year":"1997","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib68","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1200\/JCO.2012.46.5203","article-title":"Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"31","author":"Ohmachi","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib69","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1002\/cncr.23422","article-title":"Prednisone, etoposide, procarbazine, and cyclophosphamide (PEP-C) oral combination chemotherapy regimen for recurring\/refractory lymphoma: low-dose metronomic, multidrug therapy","volume":"112","author":"Coleman","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.cger.2015.08.006_bib70","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s00280-009-0941-9","article-title":"Long-term results of gemcitabine plus oxaliplatin with and without rituximab as salvage treatment for transplant-ineligible patients with refractory\/relapsing B-cell lymphoma","volume":"64","author":"Corazzelli","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cger.2015.08.006_bib71","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1093\/annonc\/mdq626","article-title":"An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma","volume":"22","author":"Witzig","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib72","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/10428194.2012.711828","article-title":"Limited-stage mantle cell lymphoma: treatment outcomes at the Princess Margaret Hospital","volume":"54","author":"Bernard","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cger.2015.08.006_bib73","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1182\/blood-2009-02-179739","article-title":"How I treat mantle cell lymphoma","volume":"114","author":"Ghielmini","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib74","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2015.08.006_bib75","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib76","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1056\/NEJMoa1200920","article-title":"Treatment of older patients with mantle-cell lymphoma","volume":"367","author":"Kluin-Nelemans","year":"2012","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib77","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib78","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood-2014-08-597914","article-title":"A\u00a0phase 1\/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed\/refractory non-Hodgkin lymphoma","volume":"125","author":"Maddocks","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib79","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/10428190701837330","article-title":"Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma","volume":"49","author":"Coleman","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.cger.2015.08.006_bib80","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1200\/JCO.2005.04.164","article-title":"Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK)","volume":"23","author":"Ghielmini","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib81","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1365-2141.2005.05777.x","article-title":"Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma","volume":"131","author":"Bauwens","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cger.2015.08.006_bib82","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib83","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cger.2015.08.006_bib84","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib85","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/1756-8722-6-45","article-title":"Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?","volume":"6","author":"Michallet","year":"2013","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib86","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1200\/JCO.2002.08.674","article-title":"Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma","volume":"20","author":"Hainsworth","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib87","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib88","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: Eastern Cooperative Oncology Group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.cger.2015.08.006_bib89","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1056\/NEJMoa1314583","article-title":"PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma","volume":"370","author":"Gopal","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib90","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cger.2015.08.006_bib91","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1182\/blood-2007-06-095331","article-title":"A\u00a0new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma","volume":"111","author":"Hoster","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.cger.2015.08.006_bib92","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma International Prognostic Index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"}],"container-title":["Clinics in Geriatric Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069015000749?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0749069015000749?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,27]],"date-time":"2022-05-27T08:14:06Z","timestamp":1653639246000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0749069015000749"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":92,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["S0749069015000749"],"URL":"https:\/\/doi.org\/10.1016\/j.cger.2015.08.006","relation":{},"ISSN":["0749-0690"],"issn-type":[{"value":"0749-0690","type":"print"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chronic Lymphocytic Leukemia and Other Lymphoproliferative Disorders","name":"articletitle","label":"Article Title"},{"value":"Clinics in Geriatric Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cger.2015.08.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}